Lyra presents additional Phase 2 LANTERN data for LYR-210 at ARS meeting

Lyra Therapeutics, Inc.

Posted slide presentation with additional Phase 2 results from LANTERN trial of LYR-210 for chronic rhinosinusitis.
Data presented at 68th Annual Meeting of the American Rhinologic Society on September 10, 2022.
Top-line results from LANTERN previously reported on April 11, 2021; this update includes further analysis.
Slide deck available on Lyra's investor website and attached as exhibit to the 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.